- Home
- RL vs INCY Comparison
RL vs INCY Comparison
Compare RL & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RL
- INCY
- Stock Information
- Founded
- RL 1967
- INCY 1991
- Country
- RL United States
- INCY United States
- Employees
- RL N/A
- INCY N/A
- Industry
- RL Apparel
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- RL Consumer Discretionary
- INCY Health Care
- Exchange
- RL Nasdaq
- INCY Nasdaq
- Market Cap
- RL 14.5B
- INCY 13.4B
- IPO Year
- RL 1997
- INCY 1993
- Fundamental
- Price
- RL $220.42
- INCY $68.07
- Analyst Decision
- RL Buy
- INCY Buy
- Analyst Count
- RL 12
- INCY 19
- Target Price
- RL $302.09
- INCY $74.38
- AVG Volume (30 Days)
- RL 868.6K
- INCY 1.8M
- Earning Date
- RL 02-06-2025
- INCY 04-29-2025
- Dividend Yield
- RL 1.48%
- INCY N/A
- EPS Growth
- RL 24.59
- INCY N/A
- EPS
- RL 10.92
- INCY 0.15
- Revenue
- RL $6,949,600,000.00
- INCY $4,241,216,999.00
- Revenue This Year
- RL $9.10
- INCY $12.23
- Revenue Next Year
- RL $4.16
- INCY $8.89
- P/E Ratio
- RL $20.39
- INCY $454.93
- Revenue Growth
- RL 5.23
- INCY 14.76
- 52 Week Low
- RL $155.96
- INCY $50.35
- 52 Week High
- RL $289.33
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- RL 24.84
- INCY 38.27
- Support Level
- RL $263.71
- INCY $68.17
- Resistance Level
- RL $273.55
- INCY $72.81
- Average True Range (ATR)
- RL 10.40
- INCY 2.29
- MACD
- RL -7.18
- INCY -0.32
- Stochastic Oscillator
- RL 7.11
- INCY 8.61
About RL Ralph Lauren Corporation
Founded by designer Ralph Lauren in 1967 in New York City, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, handbags, home goods, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, and Lauren Ralph Lauren. Distribution channels for Ralph Lauren include wholesale (department stores and specialty stores), retail (company-owned retail stores and e-commerce), and licensing.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.